Table 4. Binding of rmAb to inactivated vaccines and hemagglutination inhibition assays.
rmAb produced as described were screened by ELISA for reactivity with TIV (containing CA/07(H1pdm), VIC/210(H3), and BR/60(B)) and with the individual monovalent inactivated vaccine (MIV) constituents: CA/07(H1pdm), VIC/210(H3), and BR/60(B). Data are shown as minimum rmAb concentration (ng/ml) required to produce a 2-fold signal above negative control. “-“, no reactivity seen at concentrations ≤25 μg/mL. “NT”, not tested. rmAb were also tested in HI assays against CA/07(H1pdm), VIC/210(H3), and B/BR/60. Values are shown as minimum concentration (ng/mL) rmAb required to inhibit 4 HA units of antigen. “*“, no HI activity seen at concentrations ≤12.5 μg/mL.
| ELISA titer
|
HI titer
|
||||||
|---|---|---|---|---|---|---|---|
| rmAb | TIV | CA/07 (H1pdm) | VIC/210 (H3) | BR/60 (B) | CA/07 (H1pdm) | VIC/210 (H3) | BR/60 (B) |
|
|
|
||||||
| 046-D02 | - | - | NT | NT | * | * | * |
| 046-D11 | 1390 | - | - | - | * | * | * |
| 065-C05 | 1.9 | 1.14 | - | - | 780 | * | * |
| 065-C06 | 25000 | - | NT | NT | * | * | * |
| 065-C11 | 50 | 3.43 | 5.7 | - | * | * | * |
| 065-D01 | 5.7 | 3.43 | - | - | 98 | * | * |
| 069-A09 | 930 | 30.86 | - | - | 98 | * | * |
| 069-B03 | 25000 | 25000 | - | - | * | * | * |
| 069-B05 | 25000 | - | NT | NT | * | * | * |
| 139-22a | 1.9 | 1.14 | - | - | 98 | * | * |
| 139-23b | 25000 | - | NT | NT | * | * | * |
| 145-C09 | 150 | 3.43 | - | - | 780 | * | * |
| 145-D11 | 1.9 | 3.43 | 25000 | - | 98 | 12500 | * |
| 146-B09 | 5.7 | 1.14 | 25000 | - | 49 | * | * |
| 146-C07 | 1.9 | 1.14 | - | - | 98 | * | * |
| 146-D11 | 1.9 | 1.14 | 25000 | - | 98 | * | * |